← Leaderboards
Lynn K Gordon
University Of California Los Angeles
$2,473,958
Attributed
$2,863,688
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $397.5K · FY2009–16$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$2,863,688 · 5
VA$0 · 1
By mechanism
R01$1,524,282 · 1
R03$457,916 · 1
R21$423,500 · 1
P60$318,710 · 1
K23$139,280 · 1
I01$0 · 1
Top collaborators
- David G Telander2 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Feng Guo$3,870,377
- Edward B Garon$6,470,653
- Donald P Tashkin$15,930,292
- Sanjiv S Gambhir$44,452,033
- Ronald T Mitsuyasu$121,811,876
Others in their field
Top investigators on “Immunocytochemistry”
- Anthony N Van Den Pol · Yale University$15,503,444
- Fred H Gage · Brown University$13,660,280
- Hongjun Song · Johns Hopkins University$12,462,321
- Muhammad Ashraf · University Of Cincinnati$12,412,642
- Eliezer Masliah · University Of California San Diego$12,284,679
- Eric Klann · University Of Pittsburgh At Pittsburgh$9,943,789
Research focus
ImmunocytochemistryClinical ResearchClinical TrialsDown-RegulationPreventLaboratoriesAntibodiesAffectNovel Therapeutic InterventionCellsBlindnessLeadWestern BlottingsPolymerase Chain ReactionBaseInflammationEnzyme Linked Immunosorbent AssayHuman SubjectAutoantigensPathologic ProcessAnimal Disease ModelsApplications GrantsBiochemical PathwayCell Type
Grant awards (14)
PD-ligand, a Paradoxical Role in Experimental Uveitis Pathogenesis and Therapy$192,500
R21 · FY2016 · EY · contact PI
PD-ligand, a Paradoxical Role in Experimental Uveitis Pathogenesis and Therapy$231,000
R21 · FY2015 · EY · contact PI
Novel Therapies to Prevent Blindness Caused by Proliferative Vitreoretinopathy$362,862
R01 · FY2013 · EY · contact PI
Novel Therapies to Prevent Blindness Caused by Proliferative Vitreoretinopathy$381,960
R01 · FY2012 · EY · contact PI
Novel Therapies to Prevent Blindness Caused by Proliferative Vitreoretinopathy$381,960
R01 · FY2011 · EY · contact PI
Novel Therapies to Prevent Blindness Caused by Proliferative Vitreoretinopathy$397,500
R01 · FY2010 · EY · contact PI
Emp2: Potential Control Of Pathology In Retinal Pigment Epithelium$0
I01 · FY2009 · VA · contact PI
Beta-B1 Crystallin - a New Candidate Uveitis Autoantigen$152,500
R03 · FY2003 · EY
Beta-B1 Crystallin - a New Candidate Uveitis Autoantigen$152,500
R03 · FY2002 · EY
Giant cell arteritis: lesional microbial sequences$159,355
P60 · FY2001 · AR
Beta-B1 Crystallin - a New Candidate Uveitis Autoantigen$152,916
R03 · FY2001 · EY
IMMUNE MECHANISMS OF OCULAR INFLAMMATORY DISEASE$70,350
K23 · FY2001 · EY
Giant cell arteritis: lesional microbial sequences$159,355
P60 · FY2000 · AR
IMMUNE MECHANISMS OF OCULAR INFLAMMATORY DISEASE$68,930
K23 · FY2000 · EY